KisoJi is a next-generation antibody company developing multi-specific antibodies to improve outcomes in oncology. Using next generation sequencing, machine learning and transgenic technologies, KisoJi has developed a powerful new multi-specific antibody discovery platform that is driven by epitope mapping, enabling deliberate antibody design and engineering. Our lead product is a tri-specific antibody that targets: the dopamine 2 receptor, PD1 and CD3, which can provide tumor targeting / signaling, checkpoint inhibition, and non-activating T-cell recruitment, respectively. Other antibodies targeting cancer metabolism, cytokines, and other tumor associated antigens are also in development in our multi-specific antibody pipeline.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Quebec
Company HQ Country:
Canada
Year Founded:
2016
Main Therapeutic Focus:
Oncology
Lead Product in Development:
KJ-101
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
